Repository logo
 

Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Stephens, Amberley D  ORCID logo  https://orcid.org/0000-0002-7303-6392
Zacharopoulou, Maria 
Moons, Rani 
Fusco, Giuliana 
Seetaloo, Neeleema 

Abstract

As an intrinsically disordered protein, monomeric alpha-synuclein (aSyn) occupies a large conformational space. Certain conformations lead to aggregation prone and non-aggregation prone intermediates, but identifying these within the dynamic ensemble of monomeric conformations is difficult. Herein, we used the biologically relevant calcium ion to investigate the conformation of monomeric aSyn in relation to its aggregation propensity. We observe that the more exposed the N-terminus and the beginning of the NAC region of aSyn are, the more aggregation prone monomeric aSyn conformations become. Solvent exposure of the N-terminus of aSyn occurs upon release of C-terminus interactions when calcium binds, but the level of exposure and aSyn's aggregation propensity is sequence and post translational modification dependent. Identifying aggregation prone conformations of monomeric aSyn and the environmental conditions they form under will allow us to design new therapeutics targeted to the monomeric protein.

Description

Keywords

Benzothiazoles, Calcium, Humans, Kinetics, Mutant Proteins, Mutation, Phosphorylation, Protein Aggregates, Protein Conformation, Proton Magnetic Resonance Spectroscopy, Structure-Activity Relationship, alpha-Synuclein

Journal Title

Nat Commun

Conference Name

Journal ISSN

2041-1723
2041-1723

Volume Title

11

Publisher

Springer Science and Business Media LLC
Sponsorship
Wellcome Trust (065807/Z/01/Z)
Medical Research Council (MR/N012453/1)
Wellcome Trust (203249/Z/16/Z)
Medical Research Council (MR/K02292X/1)
Alzheimer's Research UK (ARUK-PG2013-14)
Engineering and Physical Sciences Research Council (EP/L016087/1)
G.S.K.S. acknowledges funding from the Wellcome Trust, the UK Medical Research Council (MRC), Alzheimer Research UK (ARUK), and Infinitus China Ltd. A. DS. Acknowledges funding from the European Research Grant 819644 "BioDisOrder". A.D.S. and M.Z. acknowledge Alzheimer Research UK for travel grants. M.Z. acknowledges funding from Newnham College (Cambridge) and the George and Marie Vergottis Foundation (Cambridge Trust) and the British Biophysical Society (BSS) for travel grants. P.J.W acknowledges EPSRC funding (EP/L016087/1).